 |
|
|
| Sub No. |
Submitter |
|
| 1 |
Confidential Submission |
|
| 2 |
Thornley,
Dr Stephen |
(PDF 32KB) |
| 3 |
Confidential Submission |
|
| 4 |
Confidential Submission |
|
| 5 |
Kandiah, Dr
David A |
(PDF 4KB) |
| 6 |
Eisman,
Professor John |
(PDF 40KB) |
| 7 |
Littlejohn,
Professor Geoff |
(PDF 32KB) |
| 8 |
Glendenning,
Professor Paul |
(PDF 4KB) |
| 9 |
Australian
and NZ Bone and Mineral Society |
(PDF 889KB) |
| 10 |
Oakley, Dr
Stephen |
(PDF 13KB) |
| 11 |
Major, Dr
Gabor |
(PDF 1209KB) |
| 12 |
Australian
Medical Association (AMA) |
(PDF 66KB) |
| 13 |
Inderjeeth,
Dr Charles A. |
(PDF 8KB) |
| 14 |
Chronic
Illness Alliance |
(PDF 84KB) |
| 15 |
Joint
Epilepsy Council of Australia and Epilepsy Australia |
(PDF 74KB) |
| 16 |
Generic
Medicines Industry Association Pty Ltd |
(PDF 854KB) |
| 17 |
Pharmaceutical Society of Australia |
(PDF 272KB) |
| 18 |
The
Pharmacy Guild of Australia |
(PDF 366KB) |
| 19 |
Janssen-Cilag
Australia |
(PDF 603KB) |
| 20 |
Consumers
Health Forum of Australia |
(PDF 336KB) |
| 21 |
Osteoporosis Australia |
(PDF 28KB) |
| 22 |
Paroxysmal Nocturnal Haemoglobinuria (PNH) Support Association of
Australia |
(PDF 7323KB) |
| 22a |
Attachment
to submission 22 |
(PDF 212KB) |
| 23 |
Sanofi-Aventis Australia Pty Limited |
(PDF 59KB) |
| 24 |
Arthritis Australia |
(PDF 298KB) |
| 25 |
Mental Health Council of Australia |
(PDF 57KB) |
| 26 |
Carers Australia |
(PDF 36KB) |
| 27 |
Department of Health and Ageing |
(PDF 166KB) |
| 28 |
MS Australia |
(PDF 260KB) |
| 29 |
Medicines Australia cover letter and Submission |
(PDF 60KB) (PDF 242KB) |
| 30 |
Hill, Minister John |
(PDF 204KB) |
| 31 |
AstraZeneca Pty Ltd |
(PDF 9329KB) |
| 32 |
Faunce, Dr Thomas |
(PDF 359KB) |
| 33 |
Pfizer Australia |
(PDF 482KB) |
| 34 |
Australian NPC Disease Foundation Inc (VIC) |
(PDF 531KB) |
| No. |
Answers to Questions on Notice |
|
1
|
Australian and NZ Bone and Mineral Society
(Submission no.9)
Response to questions taken on notice at public hearing 07.05.10,
received 22.05.10 |
(PDF 58KB) |
2
|
Chronic
Illness Alliance (Submission no.14)
Response to questions taken on notice at public hearing 07.05.10 |
(PDF 23KB) |
3
|
Generic
Medicines Industry Association Pty Ltd (Submission no.16)
Additional information arising from the hearing, dated 18.05.10 |
(PDF 236KB) |
4
|
The
Pharmacy Guild of Australia (Submission no.18)
Supplementary submission including response to questions taken on
notice at public hearing 07.05.10, received 14.05.10 |
(PDF 218KB) |
5
|
Janssen-Cilag
Australia (Submission no.19)
Supplementary submission received 31.05.10 |
(PDF 3005KB) |
6
|
Consumers
Health Forum of Australia (Submission no.20)
Response to questions taken on notice at public hearing 07.05.10,
received 19.05.10 |
(PDF 1205KB) |
7
|
Sanofi-Aventis Australia Pty Limited
(Submission no.23)
Response to questions taken on notice at public hearing 07.05.10,
received 31.05.10 |
(PDF 694KB) |
8
|
Arthritis Australia (Submission no.24)
Response to questions taken on notice at public hearing 07.05.10,
received 20.05.10 |
(PDF 1135KB) |
9
|
Mental Health Council of Australia
(Submission no.25)
Response to questions taken on notice at public hearing 07.05.10,
received 25.05.10 |
(PDF 72KB) |
10
|
Department of Health and Ageing (Submission
no.27)
Response to answers taken on notice at public hearing 07.05.10,
received 15.06.10 |
(PDF 1269KB) |
11
|
Medicines Australia
(Submission no.29)
Supplementary submission and response to questions taken on notice at
public hearing 07.05.10, received 31.05.10 |
(PDF 78KB) |
12
|
AstraZeneca Pty Ltd (Submission no.31)
Response to questions taken on notice at public hearing 07.05.10 and
Supplementary submission, received 31.05.10 |
(PDF 1117KB) |
13
|
Pfizer Australia (Submission no.33)
Supplementary submission received 01.06.10 |
(PDF 137KB) |
14
|
Pharmaceutical Benefits Advisory Council
Response to questions taken on notice at public hearing 07.05.10,
received 16.06.10 |
(PDF 6248KB) |